CytoTools receives confirmation of efficacy of DPCOL also against influenza viruses

- Virus-killing effect of DPOCL also confirmed with regard to influenza viruses
- Novel therapeutic approach thus also of high commercial interest beyond Corona pandemic
- Final results report on Sars-CoV-2 virus confirms efficacy of more than 95 percent

Darmstadt, 21 December 2020 - CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology holding company specializing in pharmaceuticals and medical devices, now also has the preliminary results of the test series on the efficacy of the active ingredient DPOCL on influenza viruses. As expected, the clearly virucidal ("virus-killing") effect of DPOCL was also demonstrated with regard to this virus strain. This was already demonstrated on the COVID-19-causing Sars-Cov-2 pathogen in November.

"Understandably, the second wave of COVID-19 has also led to a considerable additional workload for our cooperation partners causing delays," explains Dr. Mark-André Freyberg CEO of CytoTools. "However, the preliminary results now available reflect what was to be expected after our internal test series: DPOCL has a highly virucidal effect. Used as an inhalation component, it thus also opens up fundamentally new possibilities in the therapy of viral influenza infections."

In the cell culture experiments now completed, the efficacy of DPOCL on influenza viruses was investigated in combination with human cells. As in the tests with Sars-CoV-2, a dose-dependent effect was observed. At the highest dosage, an efficiency of over 90 percent was observed.

The company has furthermore received the final results report on the Sars-CoV-2 virus. This confirms the efficacy of DPOCL on Sars-CoV-2 viruses with an inhibition of over 95 percent.

The new results make the targeted therapeutic approach, in which DPOCL is taken as an inhalation component with physiological saline via commercially available inhalers several times per day, much more attractive to potential project partners. In addition to its efficacy against the Sars-CoV-2 virus, the compound is thus gaining importance beyond the COVID-19 pandemic. "Effective therapies against viral influenza infections are rare and generally associated with noticeable side effects," explains Dr. Dirk Kaiser, Chief Scientific Officer of CytoTools AG. "For us, this significantly increases the chances of bringing our project partnership discussions to a successful conclusion in the first quarter."

Further information on CytoTools AG, its affiliated subsidiaries and the active substance pipeline of the holding company is available on the company website at www.cytotools.de.

Contact:
CytoTools AG
Ingo Middelmenne
Investor Relations
Mobile: +49-174-9091190
Email: [email protected]

About CytoTools:

CytoTools AG is a German biotechnology holding company which translates results from basic cell biological research on cell growth and programmed cell death into new forms of therapy for the causal treatment of disease and healing. CytoTools' versatile product pipeline includes self-developed chemical compounds and biopharmaceuticals which have the potential to offer new treatment options in dermatology, cardiology, urology and oncology. CytoTools is structured as a technology holding and investment company and has holdings in the subsidiaries DermaTools Biotech GmbH (62 %) and CytoPharma GmbH (50 %).

Disclaimer
This release contains certain forward-looking statements. These reflect the opinion of CytoTools as of the date of this release. The results actually achieved by CytoTools may differ considerably from the statements made in the future-oriented statements. CytoTools is not obliged to update forward-looking statements.